Eldepryl Tablets Side Effects
Please note - some side effects for Eldepryl Tablets may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects by Body System - for Healthcare Professionals
Applies to: compounding powder; oral capsule; oral tablet; oral tablet, disintegrating; transdermal film, extended release
The most hazardous consequence of inhibition of MAO A is the potential for hypertensive crises. Such crises may be precipitated by ingestion of foods containing large amounts of exogenous amines (like tyramine) or concomitant use of medications containing indirect or mixed-acting sympathomimetic amines. At the usual therapeutic dose (10 mg per day), inhibition of MAO A generally does not occur and the manufacturer reports that patients may safely take selegiline without dietary restrictions. (For a list of foods which contain a large amount of tyramine, please see the "Interactions" section of this program). Patients should be instructed, however, to avoid over-the-counter cold remedies and other preparations which may contain vasoactive amines.
Selegiline is generally well tolerated. At the usual therapeutic dose (10 mg per day), selegiline provides selective inhibition of MAO B. At higher doses, loss of selectivity may occur and patients may be at risk of side effects related to inhibition of MAO A.
Exacerbation of preexisting ulcer disease with severe upper gastrointestinal bleeding has been reported.
Gastrointestinal side effects have been reported the most frequently. These have included constipation, flatulence, anorexia, gastroenteritis, vomiting, increased appetite, thirst, periodontal abscess, eructation, gastritis, colitis, dysphagia, tongue edema, glossitis, increased salivation, melena, tongue disorder, tooth caries. Gastrointestinal neoplasia and rectal hemorrhage have also been reported rarely. Irritation of the buccal mucosa has been reported with the use of the orally disintegrating tablet.
Patients taking levodopa-carbidopa may experience worsening of side effects attributable to levodopa. Dosage reduction of levodopa-carbidopa may be necessary.
Muscle twitch and myoclonic jerks have been reported at doses greater than 10 mg/day.
Nervous system side effects have included agitation, paresthesia, thinking abnormal, amnesia, lag cramps, tremor, vertigo, hypertonia, twitching, emotional lability, confusion, manic reaction, depersonalization, hyperkinesias, hostility, myoclonus, circumoral paresthesia, hyperesthesia, increased libido, euphoria, neurosis, paranoid reaction. Ataxia has also been reported rarely. Data from postmarketing spontaneous reporting include a seizure in a dialyzed chronic renal failure patient. A clear causal relationship to selegiline was not established.
Psychiatric side effects have included hallucinations, confusion, anxiety, mania, hypomania, psychosis, depression, other mood changes, nightmares, and hypersexuality. Reversible transvestic fetishism has been reported in a 72-year-old man with Parkinson's disease after selegiline 5 mg oral twice daily was added to his therapy for motor fluctuations. After the selegiline was stopped, his urge to wear women's clothing stopped.
Impaired memory, transient high, and increase energy have been reported at doses greater than 10 mg/day.
Cardiovascular side effects have included hypertension, vasodilation, tachycardia, migraine, syncope, atrial fibrillation, peripheral vascular disorder, and myocardial infarct.
Inhibition of MAO A may cause hypertensive crises if foods containing large amounts of exogenous amines (like tyramine) are consumed. Tyramine-rich foods and beverages should be avoided beginning on the first day of therapy with the transdermal system of selegiline 9 mg/24 hours or 12 mg/24 hours, and should continue to be avoided for two weeks after a dose reduction to 6 mg/24 hours or following the discontinuation of the 9 mg/24 hours or 12 mg/24 hours treatment. Patients receiving the higher doses should follow the recommended "Dietary Modifications Required for Patients Taking EMSAM 9 mg/24 hours and 12 mg/24 hours." If a hypertensive crisis occurs, the drug should be discontinued immediately and therapy to lower blood pressure should be instituted.
Anticholinergic effects have been reported and include dry mouth, blurred vision, urinary retention and constipation.
Hepatic side effects have included transient and persistent abnormalities of liver function tests after chronic administration.
Some investigators have recommended baseline and annual measurements of liver function tests during selegiline therapy. Others have discounted the need for such monitoring.
Dermatologic side effects have included pruritus, sweating, acne, dry skin, maculopapular rash, contact dermatitis, urticaria, herpes simplex, alopecia, vesiculobullous rash, herpes zoster, skin hypertrophy, fungal dermatitis, and skin benign neoplasm. Eczema has also been reported rarely.
Genitourinary side effects have included urinary tract infection, urinary frequency, dysmenorrhea, metrorrhagia, vaginitis, cystitis (female), hematuria (female), unintended pregnancy, dysuria (female), urinary urgency (male and female), vaginal moniliasis, menorrhagia, urination impaired (male), breast neoplasm (female), kidney calculus (female), vaginal hemorrhage, amenorrhea, breast pain and polyuria (female).
Ocular side effects have included diplopia and blurred vision.
Respiratory side effects have bronchitis, increased cough, dyspnea, asthma, pneumonia, and laryngismus. Epistaxis, laryngitis, and yawn have also been reported rarely.
Most of the application site reactions were described as erythema and most resolved spontaneously, requiring no treatment.
Local side effects have included application site reaction. It was the adverse event associated with discontinuation of the transdermal system.
Hematologic side effects have included ecchymosis, anemia, and lymphadenopathy. Leukocytosis, leukopenia, and petechiae have also been reported rarely.
Musculoskeletal side effects have included myalgia, pathological fracture, arthralgia, generalized spasm, arthritis, myasthenia, arthrosis, and tenosynovitis. Osteoporosis has also been reported rarely.
Metabolic side effects have included peripheral edema, hyperglycemia, increased SGPT, hypercholesterolemia, increased SGOT, dehydration, alcohol intolerance, hyponatremia, and increased lactic dehydrogenase. Hypoglycemic reactions, bilirubinemia, and increased alkaline phosphatase have also been reported rarely.
General side effects have included neck pain, chest pain, bacterial infections, fever, cyst, fungal infection, chills, viral infection, suicide attempt, neck rigidity, pelvic pain, photosensitivity reaction, face edema, flank pain, hernia, intentional injury, neoplasm, generalized edema, and overdose. Body odor, halitosis, heat stroke, parasitic infection, malaise, and moniliasis have also been reported rarely.Top
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.